Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Prelude Therapeutics Incorporated PRLD
$6.63
+$0.07 (1.07%)
На 18:03, 12 мая 2023
+88.54%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
302835812.00000000
-
week52high
8.90
-
week52low
3.92
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.45098700
-
EPS
-2.61000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Buy | 29 июл 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 12 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 17 мар 2022 г. |
| B of A Securities | Neutral | Buy | 15 мар 2022 г. |
| Barclays | Equal-Weight | Overweight | 28 февр 2022 г. |
| Morgan Stanley | Equal-Weight | Overweight | 09 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 15 ноя 2022 г. |
| B of A Securities | Underperform | Neutral | 21 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Chardonnet Laurent | A | 75000 | 75000 | 21 дек 2022 г. |
| Vaddi Krishna | A | 120665 | 19188 | 20 дек 2022 г. |
| Chardonnet Laurent | A | 35873 | 10000 | 08 дек 2022 г. |
| Bonita David P | A | 34300 | 34300 | 17 июн 2022 г. |
| Babler Martin | A | 31293 | 31293 | 17 июн 2022 г. |
| Dier Mardi | A | 34300 | 34300 | 17 июн 2022 г. |
| FRIEDMAN PAUL A | A | 34300 | 34300 | 17 июн 2022 г. |
| Sandor Victor | A | 34300 | 34300 | 17 июн 2022 г. |
| BAKER BROS. ADVISORS LP | A | 34300 | 34300 | 17 июн 2022 г. |
| Chardonnet Laurent | A | 24500 | 10000 | 01 июн 2022 г. |
Новостная лента
Is a Surprise Coming for Prelude Therapeutics (PRLD) This Earnings Season?
Zacks Investment Research
10 авг 2022 г. в 10:32
Prelude Therapeutics (PRLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should Know
Zacks Investment Research
22 июн 2022 г. в 11:35
The average of price targets set by Wall Street analysts indicates a potential upside of 169.5% in Prelude Therapeutics Incorporated (PRLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.